chevron_leftBack
As of 15 June 2026, Ningbo Menovo Pharmaceutical Co., Ltd. has a market cap of $2.13B USD, ranking #6748 globally and #1609 in China.
It ranks #539 in the Healthcare sector, and #210 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$2.13BUSD
14.4B CNY
Enterprise Value
$2.24BUSD
15.18B CNY
Revenue (TTM)
$231.15MUSD
1.56B CNY
EBITDA (TTM)
$51.29MUSD
347.08M CNY
Net Income (TTM)
$16.58MUSD
112.17M CNY
EBITDA Margin
22%
Profit Margin
7.2%
PE Ratio
130.6
PS Ratio
9.2
PB Ratio
5.8
EV/EBITDA
43.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Cheng Zhi Yao
open_in_new
Employees
2,404
Founded
2004
Website
menovopharm.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.4% | 9.8% | 56% | 186% | 166% | 346% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
603538
宁波美诺华药业股份有限公司 Class A
ISIN: CNE100002Y25
Shares Out.:
Shares Outstanding:
238.371M1
Shares Float:
164.472M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
62.46 CNY |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ningbo Menovo Pharmaceutical Co., Ltd.
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SSE: 600276
|
$53.92B
2K%
364.89B CNY
|
44.9
|
|
SSE: 603259
|
$49.7B
2K%
336.36B CNY
|
17.2
|
|
SHEK: 3692
|
$28.52B
1K%
223.48B HKD
|
35.7
|
|
SHEK: 1801
|
$18.8B
784%
147.32B HKD
|
162.3
|
|
SSE: 688506
|
$16.53B
677%
111.89B CNY
|
-
|
|
SHEK: 9926
|
$16.01B
653%
125.46B HKD
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
36K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
26K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
17K%
|
97.4
|
|
SIX: RO
|
$321.52B
15K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
13K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
13K%
218.9B CHF
|
20.5
|
chevron_leftBack